Evaluating the Impact of Cost on the Treatment Algorithm for Chronic Idiopathic Constipation: Cost-Effectiveness Analysis.
Journal
The American journal of gastroenterology
ISSN: 1572-0241
Titre abrégé: Am J Gastroenterol
Pays: United States
ID NLM: 0421030
Informations de publication
Date de publication:
01 10 2021
01 10 2021
Historique:
received:
29
03
2021
accepted:
19
07
2021
pubmed:
14
8
2021
medline:
28
10
2021
entrez:
13
8
2021
Statut:
ppublish
Résumé
Chronic idiopathic constipation (CIC) is a common and burdensome illness. We performed a cost-effectiveness analysis of the US Food and Drug Administration-approved CIC drugs to evaluate and quantify treatment preferences compared with usual care from insurer and patient perspectives. We evaluated the subset of patients with CIC and documented failure of over-the-counter (OTC) osmotic or bulk-forming laxatives. A RAND/UCLA consensus panel of 8 neurogastroenterologists informed model design. Treatment outcomes and costs were defined using integrated analyses of registered clinical trials and the US Centers for Medicare and Medicaid Services-supported cost databases. Quality-adjusted life years (QALYs) were calculated using health utilities derived from clinical trials. A 12-week time horizon was used. With continued OTC laxatives, CIC-related costs were $569 from an insurer perspective compared with $3,154 from a patient perspective (considering lost wages and out-of-pocket expenses). CIC prescription drugs increased insurer costs by $618-$1,015 but decreased patient costs by $327-$1,117. Effectiveness of CIC drugs was similar (0.02 QALY gained/12 weeks or ∼7 healthy days gained/year). From an insurer perspective, prescription drugs (linaclotide, prucalopride, and plecanatide) seemed less cost-effective than continued OTC laxatives (incremental cost-effectiveness ratio >$150,000/QALY gained). From a patient perspective, the cost-effective algorithm started with plecanatide, followed by choosing between prucalopride and linaclotide starting at the 145-μg dose (favoring prucalopride among patients whose disease affects their work productivity). The patient perspective was driven by drug tolerability and treatment effects on quality of life. Addressing costs at a policy level has the potential to enable patients and clinicians to move from navigating barriers in treatment access toward truly optimizing treatment choice.
Identifiants
pubmed: 34388141
doi: 10.14309/ajg.0000000000001403
pii: 00000434-202110000-00027
doi:
Substances chimiques
Laxatives
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2118-2127Informations de copyright
Copyright © 2021 by The American College of Gastroenterology.
Références
Camilleri M, Ford AC, Mawe GM, et al. Chronic constipation. Nat Rev Dis Primers 2017;3:17095.
Palsson OS, Whitehead W, Törnblom H, et al. Prevalence of rome IV functional bowel disorders among adults in the United States, Canada, and the United Kingdom. Gastroenterology 2020;158:1262-e3.
Sperber AD, Carmel S, Atzmon Y, et al. Use of the Functional Bowel Disorder Severity Index (FBDSI) in a study of patients with the irritable bowel syndrome and fibromyalgia. Am J Gastroenterol 2000;95:995–8.
Shah ND, Chitkara DK, Locke GR, et al. Ambulatory care for constipation in the United States, 1993-2004. Am J Gastroenterol 2008;103:1746–53.
Peery AF, Crockett SD, Murphy CC, et al. Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: Update 2018. Gastroenterology 2019;156:254-e11.
Aziz I, Whitehead WE, Palsson OS, et al. An approach to the diagnosis and management of Rome IV functional disorders of chronic constipation. Expert Rev Gastroenterol Hepatol 2020;14:39–46.
Oh SJ, Fuller G, Patel D, et al. Chronic constipation in the United States: Results from a population-based survey assessing healthcare seeking and use of pharmacotherapy. Am J Gastroenterol 2020;115:895–905.
Harris LA, Horn J, Kissous-Hunt M, et al. The better understanding and recognition of the disconnects, experiences, and needs of patients with chronic idiopathic constipation (BURDEN-CIC) study: Results of an online questionnaire. Adv Ther 2017;34:2661–73.
Staller K, Cash BD. Myths and misconceptions about constipation: A new view for the 2020s. Am J Gastroenterol 2020;115:1741–5.
Rao SS, Ozturk R, Laine L. Clinical utility of diagnostic tests for constipation in adults: A systematic review. Am J Gastroenterol 2005;100:1605–15.
Sommers T, Corban C, Sengupta N, et al. Emergency Department Burden of Constipation in the United States from 2006 to 2011. Am J Gastroenterol 2015;110:572–9.
Singh G, Lingala V, Wang H, et al. Use of health care resources and cost of care for adults with constipation. Clin Gastroenterol Hepatol 2007;5:1053–8.
Sethi S, Mikami S, Leclair J, et al. Inpatient burden of constipation in the United States: An analysis of national trends in the United States from 1997 to 2010. Am J Gastroenterol 2014;109:250–6.
Serra J, Pohl D, Azpiroz F, et al. European society of neurogastroenterology and motility guidelines on functional constipation in adults. Neurogastroenterol Motil 2020;32;e13762.
Bharucha AE, Bharucha AE, Dorn SD, et al. American gastroenterological association medical position statement on constipation. Gastroenterology 2013;144:211–7.
Ford AC, Moayyedi P, Lacy BE, et al. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol 2014;109(Suppl 1):S2–26.
Nelson AD, Camilleri M, Chirapongsathorn S, et al. Comparison of efficacy of pharmacological treatments for chronic idiopathic constipation: A systematic review and network meta-analysis. Gut 2017;66:1611–22.
Luthra P, Camilleri M, Burr NE, et al. Efficacy of drugs in chronic idiopathic constipation: A systematic review and network meta-analysis. Lancet Gastroenterol Hepatol 2019;4:831–44.
Shah ED, Kim HM, Schoenfeld P. Efficacy and tolerability of guanylate cyclase-C agonists for irritable bowel syndrome with constipation and chronic idiopathic constipation: A systematic review and meta-analysis. Am J Gastroenterol 2018;113:329–38.
Resneck JS. Refocusing medication prior authorization on its intended purpose. JAMA 2020;323:703–4.
Perez SL, Weissman A, Read S, et al. U.S. Internists' perspectives on discussing cost of care with patients: Structured interviews and a survey. Ann Intern Med 2019;170:S39.
Shah ED, Suresh S, Jou J, et al. Evaluating when and why patients discontinue chronic therapy for irritable bowel syndrome with constipation and chronic idiopathic constipation. Am J Gastroenterol 2020;115:596–602.
Shah ED, Salwen-Deremer JK, Gibson PR, et al. Comparing costs and outcomes of treatments for irritable bowel syndrome with diarrhea: Cost-benefit analysis. Clin Gastroenterol Hepatol 2020. [Epub ahead of print October 1, 2020.] (doi: 10.1016/j.cgh.2020.09.043)
doi: 10.1016/j.cgh.2020.09.043
Shah ED, Chang L, Salwen-Deremer JK, et al. Contrasting clinician and insurer perspectives to managing irritable bowel syndrome: Multilevel modeling analysis. Am J Gastroenterol 2021;116:748–57.
Shah ED, Chang L, Lembo A, et al. Price is right: Exploring prescription drug coverage barriers for irritable bowel syndrome using threshold pricing analysis. Dig Dis Sci 2021. [Epub ahead of print January 12, 2021.] (doi: 10.1007/s10620-020-06806-1).
doi: 10.1007/s10620-020-06806-1
Shah ED, Saini SD, Chey WD. Value-based pricing for rifaximin increases access of patients with irritable bowel syndrome with diarrhea to therapy. Clin Gastroenterol Hepatol 2019;17:2687–e11.
Shah ED, Salwen-Deremer JK, Gibson PR, et al. Pharmacologic, dietary, and psychological treatments for irritable bowel syndrome with constipation: Cost utility analysis. MDM Pol Pract 2021;6:2381468320978417.
Husereau D, Drummond M, Petrou S, et al. Consolidated health economic evaluation reporting standards (CHEERS) statement. BMC Med 2013;11:80–f1049.
Sanders GD, Neumann PJ, Basu A, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: Second panel on cost-effectiveness in health and medicine. JAMA 2016;316:1093–103.
Fitch K ed. The Rand/UCLA Appropriateness Method User's Manual. Rand: Santa Monica, 2001.
Camilleri M, Piessevaux H, Yiannakou Y, et al. Efficacy and safety of prucalopride in chronic constipation: An integrated analysis of six randomized, controlled clinical trials. Dig Dis Sci 2016;61:2357–72.
Nee JW, Johnston JM, Shea EP, et al. Safety and tolerability of linaclotide for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation: Pooled phase 3 analysis. Expert Rev Gastroenterol Hepatol 2019;13:397–406.
Brenner DM, Fogel R, Dorn SD, et al. Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: Results of two phase 3 randomized clinical trials. Am J Gastroenterol 2018;113:735–45.
Taylor DCA, Abel JL, Martin C, et al. Comprehensive assessment of patients with irritable bowel syndrome with constipation and chronic idiopathic constipation using deterministically linked administrative claims and patient-reported data: The chronic constipation and IBS-C treatment and outcomes real-world research Platform (CONTOR). J Med Econ 2020;23:1072–83.
US Census Bureau, Economics and Statistics Administration, US Department of Commerce. Households and Families. https://www.census.gov/prod/cen2010/briefs/c2010br-14.pdf (2010). Accessed February 1, 2021.
Care.com, Inc. 2018 Cost of Care Survey. ( https://www.care.com/c/stories/2423/how-much-does-child-care-cost/ . Accessed June 1, 2020.
Muennig P. Cost-effectiveness Analyses in Health: A Practical Approach. 2nd edn. Jossey-Bass: San Francisco, 2008.
Herrick LM, Spalding WM, Saito YA, et al. A case-control comparison of direct healthcare-provider medical costs of chronic idiopathic constipation and irritable bowel syndrome with constipation in a community-based cohort. J Med Econ 2017;20:273–9.
Neri L, Basilisco G, Corazziari E, et al. Constipation severity is associated with productivity losses and healthcare utilization in patients with chronic constipation. United Eur Gastroenterol J 2014;2:138–47.
Consumer Price Index (CPI) for Medical Care. U.S. Department of Labor, Bureau of Labor Statistics. ( https://www.hrsa.gov/get-health-care/affordable/hill-burton/cpi.html ). Accessed December 1, 2020 and June 1, 2020.
Parker M, Haycox A, Graves J. Estimating the relationship between preference-based generic utility instruments and disease-specific quality-of-life measures in severe chronic constipation: Challenges in practice. Pharmacoeconomics 2011;29:719–30.
Marquis P, De La Loge C, Dubois D, et al. Development and validation of the patient Assessment of constipation quality of life questionnaire. Scand J Gastroenterol 2005;40:540–51.
Marseille E, Larson B, Kazi DS, et al. Thresholds for the cost–effectiveness of interventions: Alternative approaches. Bull World Health Organ 2015;93:118–24.
Shah ED, Siegel CA. Systems-based Strategies to consider treatment costs in clinical practice. Clin Gastroenterol Hepatol 2020;18:1010–4.
Thompson AN, Cohen-Mekelburg S, Udow-Philllips M, et al. Dissecting drug pricing in gastroenterology and hepatology. Clin Gastroenterol Hepatol 2021;19:10–3.e1.
Bai G, Sen AP, Anderson GF. Pharmacy benefit managers, brand-name drug prices, and patient cost sharing. Ann Intern Med 2018;168:436–7.
Daniel H, Bornstein SS; For the Health and Public Policy Committee of the American College of Physicians. Policy recommendations for pharmacy benefit managers to stem the escalating costs of prescription drugs: A position paper from the American college of physicians. Ann Intern Med 2019;171:823.
Heidelbaugh JJ, Stelwagon M, Miller SA, et al. The spectrum of constipation-predominant irritable bowel syndrome and chronic idiopathic constipation: US Survey Assessing Symptoms, care seeking, and disease burden. Am J Gastroenterol 2015;110:580–7.
Sun SX, Dibonaventura M, Purayidathil FW, et al. Impact of chronic constipation on health-related quality of life, work productivity, and healthcare resource use: An analysis of the National Health and Wellness Survey. Dig Dis Sci 2011;56:2688–95.
Erwin K, Fitzpatrick V, Norell S, et al. Development of a framework and tool to facilitate cost-of-care conversations with patients during prenatal care. Ann Intern Med 2019;170:S62.
Henrikson NB, Banegas MP, Tuzzio L, et al. Workflow requirements for cost-of-care conversations in outpatient settings providing oncology or primary care: A qualitative, human-centered design study. Ann Intern Med 2019;170:S70.
AMITIZA (Lubiprostone) Approval Package. U.S. Food and Drug Administration. ( https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/021908Orig1s011.pdf ). Accessed December 1, 2020.
Drug Approval Package: Motegrity (Prucalopride). U.S. Food and Drug Administration. ( https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210166Orig1s000TOC.cfm ). Accessed December 1, 2020.
Carson RT, Tourkodimitris S, MacDougall JE, et al. Effect of linaclotide on quality of life in adults with chronic constipation: Results from 2 randomized, double-blind, placebo-controlled phase III trials. Gastroenterology 2010;139:e19.
Schoenfeld P, Lacy BE, Chey WD, et al. Low-dose linaclotide (72 μg) for chronic idiopathic constipation: A 12-week, randomized, double-blind, placebo-controlled trial. Am J Gastroenterol 2018;113:105–14.
DeMicco M, Barrow L, Hickey B, et al. Randomized clinical trial: Efficacy and safety of plecanatide in the treatment of chronic idiopathic constipation. Therap Adv Gastroenterol 2017;10:837–51.
Tack J, Camilleri M, Dubois D, et al. Association between health‐related quality of life and symptoms in patients with chronic constipation: An integrated analysis of three phase 3 trials of prucalopride. Neurogastroenterol Motil 2015;27:397–405.
Medicaid. National Average Drug Acquisition Cost (NADAC) Database. ( https://data.medicaid.gov/ ). Accessed June 1, 2020.
US Bureau of Labor Statistics. Employment, Hours, and Earnings From the Current Employment Statistics Survey. ( https://data.bls.gov/timeseries/CES0500000003 ). Accessed June 1, 2020.